New cancer immunotherapy
Antitumor immune surveillance has only been understood at the cell and molecular levels in the last decade. These discoveries have shown that targeted therapies, although they do not work in all patients, are incredibly accurate and effective new therapeutic weapons, and they also offer research the most fundamental of new tools, to elucidate questions that had been unanswered for decades.
The problem of oncology today is not to find the miracle drug that will eradicate all cancers, but to have at hand robust biological technologies to identify the best combination of therapeutic agents for each patient. It is clear that immunotherapy will henceforth play an important role in this modern vision of multidisciplinarity.
This book aims to present the new tools and concepts that are constantly enriching the range of our therapeutic approaches in this field where progress is rapid and events fast-moving. Some of the best French specialists in these subjects have agreed to share their knowledge and the technologies they use to offer the specialist and non-specialist oncologists the most complete and clear overview of immunotherapy today and tomorrow
• CTLA-4: from origins to antibodies
• Clinical use of anti-CTLA-4 antibodies
• Anti-PD1 and anti-PDL1 antibodies
• Modified T cells: chimeric antigen receptors (CAR)
• New control options: NK lymphocytes
• New therapeutic combinations